Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Micronanoparticled risedronate exhibits potent vaccine adjuvant effects [scRNA-Seq]

ABSTRACT: Micronanoparticled risedronate exhibits potent vaccine adjuvant effects [scRNA-Seq]

PROVIDER: PRJNA1000479 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25473436_1.fastq.gz	Fastqsanger.gz
	SRR25473436_2.fastq.gz	Fastqsanger.gz
	SRR25473437_1.fastq.gz	Fastqsanger.gz
	SRR25473437_2.fastq.gz	Fastqsanger.gz
	SRR25473438_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Micronanoparticled risedronate exhibits potent vaccine adjuvant effects

Project description:Micronanoparticled risedronate exhibits potent vaccine adjuvant effects

| PRJNA1000475 | ENA

Micronanoparticled risedronate exhibits potent vaccine adjuvant effects [RNA-Seq]

Project description:Micronanoparticled risedronate exhibits potent vaccine adjuvant effects [RNA-Seq]

| PRJNA1000477 | ENA

Micronanoparticled risedronate exhibits potent vaccine adjuvant effects [scRNA-Seq]

Project description:Nanoparticles and microparticles are widely used as vaccine adjuvants to enhance the immune response and improve the stability of antigens. While aluminum salt is one of the most common adjuvants approved for human use, its immunostimulatory capacity is suboptimal. In this study, we modified risedronate, an immunostimulant and anti‐osteoporotic drug, to create the zinc salt particle-based risedronate (Zn-RS), also termed particulate risedronate. Compared to soluble risedronate, the Zn-RS adjuvant demonstrated increased recruitment of innate cells, enhanced antigen uptake locally, and a similar antigen depot effect as aluminum salt. Furthermore, the Zn-RS adjuvant directly and quickly stimulated immune cells, accelerated the formulation of germinal centers in the lymph nodes, and facilitated the rapid production of antibodies. Importantly, the Zn-RS adjuvant exhibited superior performance in both young and aged mice, effectively protecting against respiratory diseases such as SARS-CoV-2 infection. Consequently, particulate risedronate showed great potential as a universal vaccine adjuvant, particularly beneficial for vaccines targeting the susceptible elderly.

2024-08-01 | GSE239646 | GEO

Micronanoparticled risedronate exhibits potent vaccine adjuvant effects [RNA-Seq]

2024-08-01 | GSE239643 | GEO

Micronanoparticled risedronate exhibits potent vaccine adjuvant effects

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-08-01 | GSE239649 | GEO

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with and without AS03 adjuvant

Project description:H5N1 influenza vaccine is known to induce diminished antibody responses in vaccine recipients without the use of adjuvant. We hypothesize that this is due to intrinsic defects in innate responses that could explain the poor immunogenicity of the vaccine. These innate responses may be improved with use of an adjuvant, e.g., AS03.

2021-06-29 | GSE102012 | GEO

Ex vivo Model of Functioning Human Lymph Node Reveals Role for Innate Lymphocytes and Stroma in Response to Vaccine Adjuvant

Project description:Immunological processes that underpin human immune responses to therapeutics and vaccine components, such as vaccine adjuvants, remain poorly defined due to a paucity of models that can faithfully recapitulate immune activation in lymphoid tissues. We describe precision-cut human lymph node (LN) slices as a functioning, architecturally-preserved, full-organ cross-sectional model system. Using single cell transcriptomics and multiplexed imaging we explored early inflammatory response to a potent, clinically-relevant liposomal vaccine adjuvant containing a TLR4-agonist and QS-21 saponin. Both TLR4 and NLRP3 inflammasome activation were involved in the direct initiation of the inflammatory response to adjuvant by monocytes and macrophages (Mon./Mac.) with secretion of IL-1b, but not IL-18, found to be TLR4-dependent. Innate lymphoid cells, including NK cells, were indirectly activated by Mon./Mac.-produced cytokines, signalling downstream to B cells via IFNg secretion. Resident LN stromal populations were primed both directly and indirectly by vaccine adjuvant and were instrumental in mediating inflammatory cell recruitment, particularly neutrophils.

2025-07-01 | GSE294959 | GEO

A novel compound exhibits potent anti-Candida albicans activity

Project description:A novel compound exhibits potent anti-Candida albicans activity

| PRJNA1213729 | ENA

The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in non-human primates

Project description:The induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play an important role as drivers of such responses. Despite advances in vaccine strategies, a safe and effective HIV vaccine remains a significant challenge. The use of an appropriate adjuvant is crucial to the success of HIV vaccines. Here, we assessed the saponin/MPLA nanoparticle (SMNP) adjuvant with an HIV envelope (Env) trimer, evaluating the impact of adjuvant dose on the establishment of Env-specific memory B cell responses in non-human primates.

2025-03-11 | GSE291681 | GEO

Administration of multivalent influenza virus recombinant hemagglutinin vaccine in combination-adjuvant elicits broad reactivity beyond the vaccine components

Project description:Combining variant antigens into a multivalent vaccine is a traditional approach used to provide broad coverage against antigenically variable pathogens, such as polio, human papilloma and influenza viruses. However, strategies for increasing the breadth of antibody coverage beyond the vaccine are not well understood, but may provide more anticipatory protection. Influenza virus hemagglutinin (HA) is a prototypic variant antigen. Vaccines that induce HA-specific neutralizing antibodies lose efficacy as amino acid substitutions accumulate in neutralizing epitopes during influenza virus evolution. Here we studied the effect of a potent combination adjuvant (CpG/MPLA/squalene-in-water emulsion) on the breadth and maturation of the antibody response to a representative variant of HA subtypes H1, H5 and H7. Using HA protein microarrays and antigen-specific B cell labelling, we show when administered individually, each HA elicits a cross-reactive antibody profile for multiple variants within the same subtype and other closely-related subtypes (homosubtypic and heterosubtypic cross-reactivity, respectively). Despite a capacity for each subtype to induce heterosubtypic cross-reactivity, broader coverage was elicited by simply combining the subtypes into a multivalent vaccine. Importantly, multiplexing did not compromise antibody avidity or affinity maturation to the individual HA constituents. The use of adjuvants to increase the breadth of antibody coverage beyond the vaccine antigens may help future-proof vaccines against newly-emerging variants.

2021-06-26 | GSE178932 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data